Harris Freedman , Vice President for Strategic Alliances. And now a few blurbs from from HEMISPHERX BIOPHARMA INC and http:www.tenkwizard.com Word Search Results For: Harris Freedman
Word Search Results For: Harris Freedman
Click the Red high-lighted links below to go to that section of the filing (or click HERE to go directly into filing.)
HEMISPHERX BIOPHARMA INC filed this S-1 on 07/26/1996.
oth the Company and BioAegean and received 50,000 BioAegean Options. Robert Peterson serves as Chief Financial Officer of both the Company and BioAegean and received 50,000 BioAegean Options. Sharon Will, Vice President of Investor Relations and Corporate Communications for the Company, serves as Vice President of Marketing for BioAegean and received 150,000 BioAegean Options. Harris Freedman serves as Vice President for Strategic Alliances for both the Company and BioAegean and received 150,000 BioAegean Options. Richard Piani, a director of the Company, serves as a director and the Advisor for European Affairs of BioAegean and received 50,000 BioAegean Options. Gerald Kay serves as a director for both the Company and BioAegean and received 50,000 BioAegean O
and Process Development Josephine M. Dolhancryk 33 Treasurer, Assistant Secretary Cedric C. Philipp 74 Director, Associate Secretary, Special Advisor to the Board/International Richard C. Piani 69 Director Peter W. Rodino III 43 Director, Secretary Harris Freedman 61 Vice President, Corporate Communications Sharon D. Will 36 Vice President, Investor Relations E. Gerald Kay 58 Director William A. Carter, M.D., the co-inventor of Ampligen, joined the Company in 1978, and has served as (a) the Company's Chief Scientific Officer since May 1989, (b
irectors of the Foundation Health Plan of New Jersey, an IPA/HMO providing health care services, from 1983 to 1988 and as a Director of Columbus Hospital from 1986 to 1990. Mr. Rodino earned a B.S. in Business Administration from Georgetown University in 1973 and a J.D. from Seton Hall University School of Law in 1976. 68 Harris Freedman has served as Vice President for Strategic Alliances since August 1994 and has been a private venture capitalist and business consultant for more than the past five years. He is the Secretary of Bridge Ventures, Inc. ("Bridge Ventures") and SMACS Holding Corp., both of which are private venture capital companies, positions he has held for more than five years. His business experi
-- -- -- Medical Director 1994 -- -- -- -- -- 1993 -- -- -- -- Harris Freedman 1995 112,500 -- -- 150,000 (10) -- Vice President 1994 -- -- -- 400,000 (12) -- 1993 -- -- -- -- --
se common stock at $3.50 per share granted in November 1994. (12) Rule 701 Warrants to purchase common stock at $3.50 per share granted in August 1994. (13) As of December 31, 1995, Sharon Will had 100,000 shares of 144 restricted stock valued at $228,125 using the average closing bid and asked price on December 31, 1995 of $2.28. As of December 31, 1995, Harris Freedman had 150,000 shares of Rule 144 restricted stock valued at $342,000 using the average closing bid and asked price on December 31, 1995 of $2.28. 72 Year End Option Table. The following table sets forth certain information regarding the stock options held as of December 31, 1995 by the individuals named in the abo
William A. Carter -- -- 1,091,355(1) 1,233,333(2) 292,188 -- Robert E. Peterson -- -- 6,912(3) 56,912(4) --- -- Sharon Will -- -- 341,667(5) 283,333(6) 146,094 -- Harris Freedman -- -- 975,494(7) 416,667(8) 292,188 -- - ---------- (1) Includes (i) 466,667 currently exercisable Rule 701 Warrants to purchase Common Stock at $3.50 per share; (ii) 73,728 stock options to purchase Common Stock at $3.50 per share; (iii) 960 warrants to purchase Common Stock at $3.5
on Name (#) Fiscal Year $/Share Date - ---- --- ----------- ------- ---- William A. Carter 300,000(2) 46% $1.00 5/4/05 Robert E. Peterson 50,000(2) 8% $1.00 5/4/05 Sharon Will 150,000(2) 23% $1.00 5/4/05 Harris Freedman 150,000(2) 23% $1.00 5/4/05 (1) Amounts represent hypothetical gains that could be achieved for the respective options if not exercised until the end of the option term. These gains are based on assumed rates of stock price appreciation of 5% and 10% (as required under the rules and regulations of the Securities and Exchange
--------------------- ---------------- William A. Carter 300,000 5/4/05 Chairman of the Board Chief Executive Officer Robert E. Peterson 50,000 5/4/05 Chief Financial Officer Sharon Will 150,000 5/4/05 Vice President Harris Freedman 150,000 5/4/05 (1) BioAegean Options to purchase common stock of BioAegean Corp., a subsidiary of the Company at $1.00 per share which were granted in May 1995. Employment Agreements The Company entered into an employment agreement with Sharon Will providing for her employment as Vice President for Corporate Communications and
e event that Ms. Will's employment is terminated for any reason other than breach of contract, she shall be entitled to receive accrued and unpaid compensation plus an additional three months' compensation. In July 1995, the term of Ms. Will's employment agreement was extended from one year to three years. The Company entered into an employment agreement with Harris Freedman providing for Mr. Freedman's employment as Vice President for Strategic Alliances on August 1, 1994. The agreement provides for Mr. Freedman to be employed for a one year term for a base salary of $120,000 and provides for termination of the agreement upon certain circumstances including termination by the Company or Mr. Freedman on 14 days written notice or the s
outstanding shares of the Company: Shares Officers, Directors and Beneficially Percent of Shares Principal Stockholders Owned Beneficially Owned (1) - ---------------------- ------------ ---------------------- William A. Carter 4,156,671(2) 21.1% Harris Freedman 1,025,494(3) 6.2% E. Gerald Kay 656,667(4) 4.0% Sharon D. Will 556,667(5) 3.4% Cedric C. Philipp 27,667(6) * Peter W. Rodino III 25,099(7) * Robert E. Peterson 10,368(8)
exercise price $3.50 per share. R. Douglas Hulse, Chief Operating Officer of the Company, is an Executive Director of the Sage Group. In March 1996, William A. Carter assigned and transferred 50,000 Warrants to purchase Common Stock, at $1.75 per share, to three outside parties that had loaned the Company money in 1995. These loans were repaid in 1995. In March 1996, Harris Freedman assigned and transferred 160,000 Warrants to purchase Common Stock at $1.75 per share to Sharon Will, an officer of the Company and two other shareholders. In March 1996, the Compensation Committee of the Board of Directors approved a grant of 250,000 warrants to purchase common stock at an exercise price of $3.50 per share to Michael C. Burrows. This grant
50,000 shares of the Company's Common Stock at an exercise price of $1.75 per share for each $100,000 of standby financing obligation assumed by the party, resulting in warrants to purchase an aggregate of 2,750,000 shares of Common Stock. In September 1995, the parties agreed to extend their obligations under the 1995 Standby Financing Agreement through December 31, 1996. Harris Freedman , a Vice President of the Company, and his wife are officers of Bridge Ventures. Gerald Brauser is President of Associated Funding Services, Inc. In June 1995, the Board of Directors of BioAegean Corp, a subsidiary of the Company, issued an aggregate of 1,200,000 BioAegean Options at an exercise price of $1.00 per share to its officers and directors, including certain officers and
Officer of the Company and BioAegean and received 50,000 BioAegean Options. Robert Peterson serves as Chief Financial Officer of both the Company and BioAegean and received 50,000 BioAegean Options. Sharon Will, Vice President of Investor Relations and Corporate Communications for the Company, serves as Vice President of Marketing for BioAegean and received 150,000 BioAegean Options. Harris Freedman serves as Vice President for Strategic Alliances for both the Company and BioAegean and received 150,000 BioAegean Options. Richard C. Piani, a director of the Company, serves as a director and the Advisor for European Affairs of BioAegean and 86 received 50,000 BioAegean Options. E. Gerald Kay serves as a director for both t
Brauser Note, Bridge Ventures agreed to permit the Company to collateralize these notes with the Company's patent estate, which collateral had previously been granted to Bridge Ventures. Bridge Ventures further guaranteed the Original Brauser Note with certain publicly traded common stock, which guarantee was released by Mr. Brauser in connection with the restructuring. Harris Freedman , a Vice President of the Company, and his wife are both officers of Bridge Ventures. In March and April 1995, in connection with the Bridge Financing, the Company issued Bridge Notes to certain lenders in the aggregate principal amount of $1,500,000, including a Bridge Note in the amount of $250,000 to Stephen Drescher and a Bridge Note in the amount of $150,000 to
idge Units to certain other investors. Mr. Drescher is a former director of the Company and presently serves as the Director of Corporate Finance at Monroe Parker, one of the Underwriters. Jerome Belson is a principal shareholder and director of BioAegean, a subsidiary of the Company. In March 1995, the Company received interest-free loans from William A. Carter and Harris Freedman in the amounts of $35,000 and $12,000, respectively. In March 1995, the Company repaid the loan from Dr. Carter. In April 1995, the Company repaid the loan from Mr. Freedman. In December 1992 and February 1993, the Company issued to the Tisch/Tsai Entities, in a private placement, promissory notes in the aggregate principal amount of $2,400,000 due on April 30, 1994, and
uce the exercise price of Mr. Cherry's warrants to $1.75 per share. Because Mr. Cherry has not advised the 88 Company of his election, the Company has reduced the exercise price of his warrants to $1.75 per share. As of July, 1995, the Company has repaid the entire principal amount of the Note, including accrued interest. Harris Freedman , a Vice President of the Company, and his wife are officers of Bridge Ventures. In October and November 1994, the Company granted Rule 701 Warrants to purchase 20,000 shares of Common Stock at $3.50 per share to E. Gerald Kay, Cedric C. Philipp and Peter Rodino III, directors of the Company and Maryann Charlap Azzato, a former director of the Company. In addition,
no III, directors of the Company and Maryann Charlap Azzato, a former director of the Company. In addition, the Company granted the following Rule 701 Warrants to purchase shares of Common Stock at $3.50 per share: 1,400,000 warrants to William A. Carter; 200,000 warrants to Sharon Will, Vice President of Investor Relations and Corporate Communications; and 400,000 warrants to Harris Freedman , Vice President for Strategic Alliances. From July 1994 to November 1994, the Company completed a private placement in which it sold 2,050,000 shares of Common Stock to certain accredited investors for an aggregate consideration of $1,025,000 (the "1994 Common Stock Financing"). In connection with the private placement, Bridge Ventures introduced a number of inve
nces. From July 1994 to November 1994, the Company completed a private placement in which it sold 2,050,000 shares of Common Stock to certain accredited investors for an aggregate consideration of $1,025,000 (the "1994 Common Stock Financing"). In connection with the private placement, Bridge Ventures introduced a number of investors and lenders to the Company. Harris Freedman , Vice President of the Company, and his wife are officers of Bridge Ventures. In conjunction with the 1994 Common Stock Financing, the Company agreed to collateralize certain of its patents until the earlier of the effectiveness of the initial public offering or the consummation of corporate alliances or licensing arrangement which provide sufficient operating capital a
ned certain other patents to BioPro (the "BioPro License"), Core BioTech (the "CoreBiotech License") and BioAegean (the "BioAegean License"). Bridge Ventures, which has rights in the Company's patents pursuant to the collateralization of such patents in connection with the 1994 Common Stock Financing, agreed to release its rights in the licensed or assigned patents. Harris Freedman , the Vice President for Strategic Alliances for the Company and BioAegean, and his wife are officers of Bridge Ventures. In May 1994, the Company entered into an agreement to borrow $100,000 from Bridge Ventures for 60 days in exchange for warrants to purchase 92,160 shares of Common Stock at $3.50 per share. In August 1994, the $100,000 loan was converted to 200,000 s
90 transferred 150,000 of its shares of Common Stock to Gerald Kay, a director of the Company. In addition, Bridge Ventures received a $50,000 consulting fee for general business and financial consulting services rendered from January 1994 to July 1994, which it converted into 100,000 shares of Common Stock as part of the 1994 Common Stock Financing. Harris Freedman , the Company's Vice President, and his wife are officers of Bridge Ventures. Pursuant to the agreement with Bridge Ventures, Messrs. Kay, Philipp and Rodino were elected to the Board of Directors. In November 1994, each of Bridge Ventures and Gerald Kay sold 50,000 shares of Common Stock at a price of $.50 per share to Worldwide Marketing. Sharon Will, an officer of the Comp
1 - 20 out of 23
|
